CMH SCIENTIFICTOPOLAI · DECISION CONTROLLER
ORCHESTRATION VIEW

TopolAI

Returns a decision rather than a score: use it, keep going, acquire selectively, change the measurement, add a modality, reacquire, or abstain.

current decision
CONTINUE_SELECTIVELY

Keep the current observer and structural representation; acquire the tested added information only in pre-identified ambiguous regions, then reassess.

CMH GUARDexecution gate: ALLOW / review destination separately
NPISWhat does the substrate distinguish?UNRESOLVED SUBSET
Material local branching remains.
→
OptiCeilHow much is recoverable?NEAR FRONTIER
Little model-only headroom in tested representation.
→
TotemicAIWhat structure must persist?COHERENT
Sparse landmarks remain stable.
→
AcquireWhat tested observation adds value?CONCENTRATED VALUE
Added measurement helps selected regions.
→
ControllerWhat should happen now?ACT
Acquire selectively, then loop.
Try decision states
RESULT

Return an explicit action state, not only a score.

EVIDENCE

Preserve component-specific evidence so one metric cannot overrule the others silently.

BOUNDARIES

No automatic proof of mechanism, causal effect, or universal information ceiling.

NEXT ACTION

Execute only the supported measurement/model action, then reassess the updated substrate.

This browser demo illustrates the public controller contract. It does not run protected NPIS, OptiCeil, TotemicAI, Acquire, or controller-policy estimators.

Validation & data provenance

TopolAI’s action states are demonstrated here using separately validated component outputs; the heterogeneous validation cohorts are reported separately rather than pooled.

NPIS direct cohorts56,199 individuals · 408,014 longitudinal states across ADNI, PPMI, PRO-ACT ALS, HRS, and Add Health
OptiCeil imaging + sensorCASCADE: 914 segments / 312 neurons / 146,962 samples; BUT PPG: 82,966 samples / 3,840 recordings / 38 subjects
TotemicAI AMLGSE221578 · 3 held-out patient response fields · 39,590 perturbation-response observations
Acquire ALS / COPD / perturbationPRO-ACT: 8,260 participants / 70,746 transitions; COPDGene: 785 participants; GSE254742 cross-replicate dose-grid test
Boundary: these heterogeneous units are shown separately and are not summed into a single “sample size.” TopolAI coordinates evidence, recoverability, structural memory, acquisition, and reassessment; it does not turn retrospective component validation into a prospective clinical-control claim.
Dataset / validation references
  1. Rupprecht P, Carta S, Hoffmann A, et al. Nat Neurosci. 2021. doi:10.1038/s41593-021-00895-5.
  2. Atassi N, Berry J, Shui A, et al. Neurology. 2014. doi:10.1212/WNL.0000000000000951.
  3. NCBI GEO: GSE221578 and GSE254742.
  4. Regan EA, Hokanson JE, Murphy JR, et al. COPD. 2010. doi:10.3109/15412550903499522.
  5. Ewing MA. Nonparametric Information Sufficiency. Research Square. 2026. doi:10.21203/rs.3.rs-10897971/v1.
  6. Ewing MA. Intelligence Cannot Recover What the Instrument Does Not Record. Research Square. 2026. doi:10.21203/rs.3.rs-10959134/v1.
  7. Ewing MA. Information-Guided Inverse Design of Calcium-Imaging Acquisition with TopolAI. Research Square. 2026. doi:10.21203/rs.3.rs-10898326/v1.
  8. Ewing MA. Information, Not AI Model Sophistication, Limits Resolution of Disease Progression in COPDGene. Research Square. 2026. doi:10.21203/rs.3.rs-10898573/v1.